McClutchy Courteney, McKone Mark, Sussman Annalize, Barry Julia, Carter Wright S, Madden Lyndsay L, Ruckart Kathryn
Department of Otolaryngology-Head and Neck Surgery, Wake Forest University School of Medicine, Winston-Salem, NC.
Wake Forest University School of Medicine, Winston-Salem, NC.
J Voice. 2025 Jan 28. doi: 10.1016/j.jvoice.2025.01.004.
Chronic cough poses diagnostic and treatment challenges due to its often multifactorial nature. Chronic cough associated with laryngeal hypersensitivity is linked to sensory neuropathy of the superior laryngeal nerve and can be complex to manage. Superior laryngeal nerve (SLN) blocks are increasingly being utilized by laryngologists to treat refractory chronic cough with the intent of reducing inflammation and nerve hypersensitivity. This scoping review aims to provide an overview of the current literature examining the efficacy of SLN blocks for treatment of chronic cough, identify knowledge gaps, and guide future studies.
A search strategy was developed in collaboration with a medical librarian and run in Ovid Medline, Embase (Elsevier), Web of Science Core Collection (Clarivate), CINAHL Ultimate (Ebscohost), Cochrane, and Google Scholar (via Harzing's Publish or Perish). Search scope was from the inception of each database to March 5, 2024. Inclusion criteria were broad and focused on any study that utilized SLN block(s) for the treatment of chronic cough. The searches yielded 1264 articles that were loaded into Covidence systematic review software for deduplication and screening. Title and abstract and then full-text screening were performed.
Twelve studies met inclusion criteria. Study designs varied, including retrospective reviews, case series, and one placebo-controlled trial. Outcome measures included validated patient-reported cough-specific quality of life measures and/or subjective patient reports. The number of blocks primarily ranged from an average of 2-4 per patient, with follow-up durations ranging anywhere from 2 weeks to 22.5 months. Adverse effects were minimal and primarily self-limiting. Other reported interventions included behavioral cough suppression therapy, used in conjunction with SLN blocks, and neuromodulators, which were often trialed prior to SLN therapy. All 12 studies reported improvement in cough, and while several studies reported significant improvements in patient-reported outcomes using Cough Severity Index and Leicester Cough Questionnaire questionnaires, only eight studies provided statistical testing with P values. The remaining studies did not perform statistical analyses or report confidence intervals, instead presenting descriptive or qualitative results.
Literature on the efficacy of SLN blocks for chronic cough reveals consistent positive outcomes. There is a need for randomized controlled trials, systematic studies with larger cohorts, longitudinal follow-up, and further comparison of ipsilateral versus bilateral blocks to determine the efficacy of SLN blocks for treatment of chronic cough.
慢性咳嗽因其通常具有多因素性质,给诊断和治疗带来了挑战。与喉感觉过敏相关的慢性咳嗽与喉上神经感觉神经病变有关,管理起来可能很复杂。喉科医生越来越多地使用喉上神经(SLN)阻滞来治疗难治性慢性咳嗽,目的是减轻炎症和神经超敏反应。本综述旨在概述当前研究SLN阻滞治疗慢性咳嗽疗效的文献,找出知识空白,并指导未来的研究。
与医学图书馆员合作制定了检索策略,并在Ovid Medline、Embase(爱思唯尔)、科学网核心合集(科睿唯安)、CINAHL终极版(EBSCOhost)、Cochrane和谷歌学术(通过Harzing的Publish or Perish)中进行检索。检索范围从每个数据库创建之初到2024年3月5日。纳入标准宽泛,重点关注任何使用SLN阻滞治疗慢性咳嗽的研究。检索共得到1264篇文章,将其导入Covidence系统评价软件进行重复数据删除和筛选。先进行标题和摘要筛选,然后进行全文筛选。
12项研究符合纳入标准。研究设计各不相同,包括回顾性综述、病例系列研究和一项安慰剂对照试验。结局指标包括经过验证的患者报告的咳嗽特异性生活质量指标和/或患者主观报告。阻滞次数主要为每位患者平均2 - 4次,随访时间从2周到22.5个月不等。不良反应轻微,主要为自限性。其他报告的干预措施包括与SLN阻滞联合使用的行为性咳嗽抑制疗法,以及在SLN治疗前经常试用的神经调节剂。所有12项研究均报告咳嗽有改善,虽然有几项研究报告使用咳嗽严重程度指数和莱斯特咳嗽问卷等患者报告结局有显著改善,但只有8项研究提供了P值的统计检验。其余研究未进行统计分析或报告置信区间,而是呈现描述性或定性结果。
关于SLN阻滞治疗慢性咳嗽疗效的文献显示出一致的积极结果。需要进行随机对照试验、更大队列的系统研究、纵向随访,以及同侧与双侧阻滞的进一步比较,以确定SLN阻滞治疗慢性咳嗽的疗效。